10-K/A: Marizyme Restates 2023 Financials, Cites Material Weakness in Internal Controls

Marizyme, Inc. restated its 2023 financial statements due to errors in convertible note accounting and identified a material weakness in its internal controls over financial reporting.

Summary

• Marizyme, Inc. is restating its financial statements for the year ended December 31, 2023, and interim periods ending June 30, 2023, and September 30, 2023.
• The restatement addresses errors in the accounting for convertible notes and warrants issued in a Units Private Placement.
• Specifically, the difference between the reacquisition price and the net carrying amount of extinguished debt was incorrectly recorded.
• The fair market value of warrants attached to the convertible notes was also adjusted, impacting additional paid-in capital and the loss on extinguishment.
• The restatement had no impact on total net cash flows.
• Management identified a material weakness in internal controls over financial reporting related to the errors.
• The company plans to enhance processes by increasing accounting staff, providing training, and implementing risk assessment procedures.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• As of December 31, 2023, the Company had an accumulated deficit of approximately $155.53 million.
• The Company defaulted under the Convertible Notes, and as a result, the Convertible Note holders may accelerate amounts owed under such Convertible Notes and seek to take possession of the assets securing our obligations.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including a restatement, material weakness in internal controls, and a going concern warning, leading to a negative sentiment.

Positives

• The restatement had no impact on total net cash flows from operating, investing or financing activities.
• The company is taking steps to remediate the material weakness in internal controls.

Negatives

• The company is restating its financial statements due to accounting errors.
• A material weakness in internal controls over financial reporting has been identified.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• As of December 31, 2023, the Company had an accumulated deficit of approximately $155.53 million.
• The Company defaulted under the Convertible Notes, and as a result, the Convertible Note holders may accelerate amounts owed under such Convertible Notes and seek to take possession of the assets securing our obligations.

Risks

• Failure to remediate the material weakness in internal controls could have a material adverse effect on the company's business and stock price.
• The company may not be able to raise additional capital.
• The holders of the Convertible Notes may seek to take possession of the assets securing our obligations.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.

Future Outlook

The company expects to incur significant and increasing operating losses for the next several years as it expands its acquisition efforts, continues clinical trials, acquires, or licenses technologies, advance other medical devices into clinical development, complete clinical trials, seek regulatory approval and, if it receives FDA approval, commercialize its products.

Industry Context

The medical device and life science industry is characterized by intense competition and regulatory scrutiny. The company's ability to compete depends on its ability to develop and commercialize innovative products and comply with applicable regulations.

Management Changes

Related Party Transactions

• During the year ended December 31, 2023, the Company incurred $ 288,000 (2022 $ 172,800 ) and settled $ 280,347 (2022 $ 172,800 ) in professional services rendered by related parties of the Company.
• The services were provided by entities which are controlled by management and are pursuant to various consulting agreements.
• During the year ended December 31, 2023, the Company also incurred $ 1,293,500 in compensation to Directors and Executive Officers for their services rendered (2022 $ 1,064,000 ) and settled $ 1,071,000 (2022 $ 1,060,000 ).
• Additionally, as part of the Somahlution acquisition in 2020, the Company recorded a prepaid royalty to the stockholders of Somahlution.
• The former primary beneficial owner is Dr. Vithal Dhaduk, currently a director, and significant stockholder of the Company.

Stakeholder Impact

• The restatement and material weakness in internal controls could negatively impact investor confidence.
• The company's ability to continue as a going concern is uncertain, which could impact stakeholders.
• The default under the Convertible Notes could lead to legal action and potential loss of assets.

Next Steps

• The company plans to enhance processes by increasing accounting staff, providing training, and implementing risk assessment procedures.
• The company intends to resume the listing process with Nasdaq or another national securities exchange when the Company is able to meet securities exchange listing requirements and standards.

Key Dates

Keywords

restatement, convertible notes, material weakness, internal controls, financial reporting, warrants, Marizyme, going concern, default